Alsop K, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663
Antoniou A, et al. Am J Hum Genet. 2003; 72(5):1117-1130.
Banez LL et al. (2007). Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 298(19):2275–2280.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
Draisma G et al. (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 101(6):374–383.
Easton DF, et al. Am J Hum Genet. 1995;56(1):265-271
Ford D, et al. Lancet. 1994;343(8899):692-695.
National Cancer Institute. BRCA 1 and BRCA 2: Cancer Risk and Genetic testing. Available at http://www.cancer.gov/cancertopics/genetics/brca-fact-sheet#r1.
Ovarian Cancer National Alliance. Treatment. Available at http://www.ovariancancer.org/about/treatmeant/.
Rawla P (2019). Epidemiology of Prostate Cancer. World J Oncol. 10(2): 63–8.
Serefoglu EC et al. (2013). How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J. May-Jun; 7(5-6)
Struewing JP, et al. N Engl J Med. 1997;336(20):1401-1408
U.S. Food and Drug Administration. Personalized medicine and companion diagnostics go hand-in-hand. Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm407328.html